LENZ Therapeutics to Participate in Upcoming Investor Conferences
LENZ Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or "LENZ" or the "Company"), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences:
洛杉磯，2024年11月12日（環球新聞社） - LENZ Therapeutics，Inc.（納斯達克：LENZ或「 LENZ」或「公司」），一家處於臨床前階段的生物藥公司，專注於開發和商業化第一款也是唯一的以乙硫胺鹼爲基礎的眼用滴眼液，用於改善老花眼的近視能力，今天宣佈公司管理層將參加以下即將舉行的投資者會議：
Jefferies London Healthcare Conference (London, UK)
Management will participate in one-on-one meetings from Tuesday, November 19th through Thursday, November 21st, 2024.
傑富瑞倫敦健康醫療大會（倫敦，英國）
管理層將參加從2024年11月19日星期二至11月21日星期四的一對一會議。
Piper Sandler 36th Annual Healthcare Conference (New York, NY)
Management is scheduled to participate in a fireside chat on Tuesday, December 3rd, 2024 at 3:30pm ET and will participate in one-on-one meetings.
派傑投資第36屆年度醫療保健大會（紐約，紐約州）
管理層計劃於2024年12月3日星期二下午3:30參加爐邊聊天，並將參加一對一會議。
7th Annual Evercore HealthCONx Conference (Coral Gables, FL)
Management is scheduled to participate in a fireside chat on Wednesday, December 4th, 2024 at 7:30 AM ET and will participate in one-on-one meetings.
第七屆evercore HealthCONx大會（佛羅里達州科勒蓋布斯）
管理層計劃於2024年12月4日星期三上午7:30參與爐邊聊天，並將參加一對一會議。
Citi 2024 Global Healthcare Conference (Miami, FL)
Management is scheduled to participate in a panel discussion titled, "Eyes Wide Open on Ophthalmology" on Thursday, December 5, 2024 at 1:45 PM ET and will participate in one-on-one meetings.
Citi 2024全球醫療保健大會（佛羅里達州邁阿密）
管理層計劃於2024年12月5日星期四下午1:45參與名爲「眼科醫療保健方面的明智選擇」的專題討論，並將參加一對一會議。
A live audio webcast of the Piper Sandler Healthcare Conference fireside chat can be accessed here and on the LENZ Therapeutics website at in the Investors & Media section. A replay of the webcast will be available on the Company's website for 12 months following the event.
Piper Sandler醫療保健大會爐邊聊天的現場音頻網絡廣播可在LENZ Therapeutics網站投資者與媒體部分進行訪問。 派傑投資將在活動結束後的12個月內在公司網站上提供網絡廣播的重播。
About LENZ Therapeutics
LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in patients with presbyopia. LENZ's product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. The U.S. Food and Drug Administration (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025 for LNZ100. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for "all eyes, all day". LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
關於LENZ Therapeutics
LENZ Therapeutics是一家面向未商業化的生物製藥公司，專注於開發和商業化第一款也是唯一一款基於乙膽鹼的眼藥水，以改善患老視症的患者的近視能力。LENZ的藥物候選品LNZ100是一種無防腐劑、一次性使用的每日一次眼藥水，含有乙膽鹼。LNZ100在註冊啓動階段3的CLARITY研究中進行評估，作爲老視症治療的潛在療法，這是一種影響全球約18億人和美國約12800萬人的控件。美國食品藥品監督管理局（FDA）已經爲LNZ100指定了處方藥用戶費法案（PDUFA）的目標行動日期爲2025年8月8日。LENZ致力於商業化一種理想的藥物老視症解決方案，提升了"全球貨幣，全天候"的視力。LENZ總部位於加利福尼亞州聖地亞哥。欲了解更多信息，請訪問：LENZ-Tx.com。
Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
聯繫人：
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
譯文內容由第三人軟體翻譯。
